Search

Displaying results 4381 - 4390 of 10000 in total
  1. Drug

    NUC B1000

    go.drugbank.com/drugs/DB05242
    Experimental

    On January 11, 2008, it was announced that NUC B1000 was entering a phase 1 human safety study of its experimental treatment for chronic Hepatitis B virus (HBV) infection. … NUC B1000 is an expressed interfering RNA (eiRNA)- based product consisting of a plasmid DNA construct designed to produce four short interfering RNA (siRNA) molecules, formulated with a proprietary cationic-lipid

  2. Drug

    Mitoquinone

    go.drugbank.com/drugs/DB05063
    Investigational

    Mitochondrial dysfunction also has been shown to represent an early critical event in the pathogenesis of the sporadic form of Parkinson's disease. … In 2004, a genomic study of hereditary early-onset Parkinson's disease demonstrated a direct molecular link between mitochondrial dysfunction and the pathogenesis of Parkinson's disease.

  3. Drug

    Mirococept

    go.drugbank.com/drugs/DB06492
    Experimental

    It consists of the first three short consensus domains of human complement receptor 1 (CR1), manufactured in recombinant bacteria and modified with a membrane-targeting amphiphilic peptide based on the … It is a truncated form of the human Complement Receptor 1 (CR1) linked to a unique Prodaptin™ construct that regulates the over-production of complement at the cell surface, which occurs in inflammation

  4. Drug

    Aspartame

    go.drugbank.com/drugs/DB00168
    InvestigationalNutraceutical

    Flavoring agent sweeter than sugar, metabolized as phenylalanine and aspartic acid.

    Synonyms: 3-Amino-N-(alpha-carboxyphenethyl)succinamic acid N-methyl ester, 3-Amino-N-(α-carboxyphenethyl)succinamic acid N-methyl esterCategories: Compounds used in a research, industrial, or household setting
  5. Drug

    SNS-314

    go.drugbank.com/drugs/DB06134
    Investigational

    SNS-314 inhibits tumor growth in a variety of preclinical models, and it is now being tested in single agent Phase 1 studies in patients with advanced solid tumours.

  6. Drug

    Fasinumab

    go.drugbank.com/drugs/DB12157
    Investigational

    [A241190] It has since been recognized for its role in nociceptive signaling transduction and has thus become an attractive target in the treatment of chronic pain conditions. … It is currently under investigation for the treatment osteoarthritic pain[A241045] and has demonstrated significantly greater pain relief and functional improvement as compared to standard therapy (i.e

  7. Drug

    NOX-700

    go.drugbank.com/drugs/DB05464
    Experimental

    NOX-700, an new orally active dithiocarbamate-based nitric oxide (NO) blocking agent that is in development for the treatment of diabetes mellitus (type 2 diabetes). … In animal studies, NOX-700 lowered serum glucose, improved glucose tolerance, and reduced the percentage of total glycated hemoglobin.

  8. Drug

    MIP-1095 I-131

    go.drugbank.com/drugs/DB14978
    Investigational

    MIP-1095 I-131 is under investigation in clinical trial NCT03030885 (Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)).

  9. Drug

    Eprodisate

    go.drugbank.com/drugs/DB06405
    Investigational

    Eprodisate slows the decline of renal function in AA amyloidosis.

  10. Drug

    Mitumomab

    go.drugbank.com/drugs/DB06462
    Experimental

    Mitumomab, an anti-BEC-2 monoclonal antibody derived from mice, was previously studied to treat small cell lung carcinoma in combination with BCG vaccination.